These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 34479103)

  • 1. Progress in the development of small molecular inhibitors of the Bruton's tyrosine kinase (BTK) as a promising cancer therapy.
    Liu XJ; Xu-Liu ; Pang XJ; -Ying Yuan X; Yu GX; Li YR; Guan YF; Zhang YB; Song J; Zhang QR; Zhang SY
    Bioorg Med Chem; 2021 Oct; 47():116358. PubMed ID: 34479103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.
    Liu J; Chen C; Wang D; Zhang J; Zhang T
    Eur J Med Chem; 2021 May; 217():113329. PubMed ID: 33740548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
    Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J
    Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based virtual screening and biological evaluation of novel small-molecule BTK inhibitors.
    Lin TE; Sung LC; Chao MW; Li M; Zheng JH; Sung TY; Hsieh JH; Yang CR; Lee HY; Cho EC; Hsu KC
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):226-235. PubMed ID: 34894949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel BTK PROTACs for B-Cell lymphomas.
    Zhao Y; Shu Y; Lin J; Chen Z; Xie Q; Bao Y; Lu L; Sun N; Wang Y
    Eur J Med Chem; 2021 Dec; 225():113820. PubMed ID: 34509879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
    Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X
    Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of pyrido[3,4-b]indol-1-one derivatives as novel non-covalent Bruton's tyrosine kinase (BTK) inhibitors.
    Dou D; Sha W; Diao Y; Su R; Qiao Y; Yu Z; Zhao Z; Li H; Chen Z; Xu Y
    Bioorg Chem; 2022 Feb; 119():105541. PubMed ID: 34910982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HZ-A-005, a potent, selective, and covalent Bruton's tyrosine kinase inhibitor in preclinical development.
    Huang W; Wang S; Zhang Z; Zhang C; Zeng S; Liang M; Shen Z; Liu X
    Bioorg Chem; 2020 Dec; 105():104377. PubMed ID: 33091668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
    Teng Y; Lu X; Xiao M; Li Z; Zou Y; Ren S; Cheng Y; Luo G; Xiang H
    Eur J Med Chem; 2020 Aug; 199():112339. PubMed ID: 32402933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton's tyrosine kinase inhibitors.
    Diao Y; Fang X; Song P; Lai M; Tong L; Hao Y; Dou D; Liu Y; Ding J; Zhao Z; Xie H; Li H
    Bioorg Med Chem; 2019 Aug; 27(15):3390-3395. PubMed ID: 31221612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationship investigation for imidazopyrazole-3-carboxamide derivatives as novel selective inhibitors of Bruton's tyrosine kinase.
    Zhang D; Xu G; Zhao J; Wang Y; Wu X; He X; Li W; Zhang S; Yang S; Ma C; Jiang Y; Ding Q
    Eur J Med Chem; 2021 Dec; 225():113724. PubMed ID: 34391034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
    Joseph RE; Amatya N; Fulton DB; Engen JR; Wales TE; Andreotti A
    Elife; 2020 Nov; 9():. PubMed ID: 33226337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
    Guo X; Yang D; Fan Z; Zhang N; Zhao B; Huang C; Wang F; Ma R; Meng M; Deng Y
    Eur J Med Chem; 2019 Sep; 178():767-781. PubMed ID: 31234030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.
    Buhimschi AD; Armstrong HA; Toure M; Jaime-Figueroa S; Chen TL; Lehman AM; Woyach JA; Johnson AJ; Byrd JC; Crews CM
    Biochemistry; 2018 Jul; 57(26):3564-3575. PubMed ID: 29851337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma.
    Ran F; Liu Y; Chen X; Zhuo H; Xu C; Li Y; Duan X; Zhao G
    Bioorg Chem; 2021 Jul; 112():104968. PubMed ID: 34000704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018).
    Feng Y; Duan W; Cu X; Liang C; Xin M
    Expert Opin Ther Pat; 2019 Apr; 29(4):217-241. PubMed ID: 30888232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.
    Gozzetti A; Candi V; Brambilla CZ; Papini G; Fabbri A; Bocchia M
    Anticancer Agents Med Chem; 2017; 17(8):1040-1045. PubMed ID: 27697038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL.
    Ran F; Liu Y; Liu M; Zhang D; Wang P; Dong J; Tang W; Zhao G
    Bioorg Chem; 2019 Aug; 89():102943. PubMed ID: 31031018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
    Guo Y; Liu Y; Hu N; Yu D; Zhou C; Shi G; Zhang B; Wei M; Liu J; Luo L; Tang Z; Song H; Guo Y; Liu X; Su D; Zhang S; Song X; Zhou X; Hong Y; Chen S; Cheng Z; Young S; Wei Q; Wang H; Wang Q; Lv L; Wang F; Xu H; Sun H; Xing H; Li N; Zhang W; Wang Z; Liu G; Sun Z; Zhou D; Li W; Liu L; Wang L; Wang Z
    J Med Chem; 2019 Sep; 62(17):7923-7940. PubMed ID: 31381333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
    Sharma A; Thelma BK
    J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.